Intensity Therapeutics Management
Management criteria checks 2/4
Intensity Therapeutics' CEO is Lew Bender, appointed in Apr 2012, has a tenure of 12.75 years. total yearly compensation is $1.24M, comprised of 44.8% salary and 55.2% bonuses, including company stock and options. directly owns 13.38% of the company’s shares, worth $3.56M. The average tenure of the management team and the board of directors is 2.8 years and 7.6 years respectively.
Key information
Lew Bender
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 44.8% |
| CEO tenure | 12.8yrs |
| CEO ownership | 13.4% |
| Management average tenure | 2.8yrs |
| Board average tenure | 7.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$15m |
| Dec 31 2023 | US$1m | US$553k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$7m |
| Dec 31 2022 | US$995k | US$493k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$9m |
| Dec 31 2021 | US$1m | US$434k | -US$8m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$902k | US$410k | -US$6m |
Compensation vs Market: Lew's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD649.25K).
Compensation vs Earnings: Lew's compensation has increased whilst the company is unprofitable.
CEO
Lew Bender (65 yo)
12.8yrs
Tenure
US$1,235,740
Compensation
Mr. Lewis H. Bender, also known as Lew, M.S., M.A., M.B.A., is the Founder of Intensity Therapeutics, Inc. and serves as its Chief Executive Officer and President since April 2012 and also serves as its Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | US$1.24m | 13.38% $ 3.6m | |
| Chief Financial Officer | 1.1yrs | US$694.38k | no data | |
| Principal Accounting Officer & Controller | 7.8yrs | US$527.29k | 0.044% $ 11.8k | |
| Executive Vice President of Corporate Finance | 1.6yrs | US$75.09k | no data | |
| Executive Vice President of Clinical Development | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
62.5yo
Average Age
Experienced Management: INTS's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | US$1.24m | 13.38% $ 3.6m | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 6.7yrs | US$26.75k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$31.75k | 0% $ 0 | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Director | 2yrs | US$28.75k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.6yrs
Average Tenure
63yo
Average Age
Experienced Board: INTS's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:58 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intensity Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Kumaraguru Raja | Brookline Capital Markets |
| Vadim Merkulov | Freedom Broker |